

**Alain ARMENGAUD AINÉ**  
Licencié es Sciences

**Chantal PEAUCELLE**  
Docteur de spécialité Chimie

**Bernard MICHARDIÈRE**  
Ingénieur ECP - Docteur Ingénieur

Conseils en Propriété Industrielle (BM)  
Mandataires agréés auprès de l'Office  
Européen des Brevets et de l'OHMI  
(Marques communautaires)

**Anne GAILLARDIN**  
Maîtrise de Droit des Affaires et Fiscalité  
DESS de Propriété Industrielle  
Conseil en Propriété Industrielle (M)  
Mandataire agréée auprès de l'OHMI

**Eric DONNEGER**  
Maîtrise de Chimie-Physique  
D.E.A. Génie des Procédés Industriels  
Diplômé C.E.I.P.I. - (BM)

**Blandine TARRERE**  
Ingénieur C.P.E.  
(Option Chimie du Vivant et  
Biotechnologies)

Conseil en Propriété Industrielle (B)  
Mandataire agréée auprès de  
l'Office Européen des Brevets

**Patrick MONLOUIS**  
Ingénieur ENSAM  
(Option Matériaux)

Services Administratifs  
Annuités : **Colombe ANGER**  
**Joëlle PIERRE-DOUBLET**  
Comptabilité : **Catherine FOIN**  
Marques, Dessins et Modèles :  
**Caroline de BONTIN**

**CABINET ARMENGAUD AINÉ** FONDÉ EN 1836

Membre d'une association agréée - Le règlement par chèque est accepté.  
S.C.P. au capital de 20 123,27 € - R.C.S. Paris D 392 004 404 - Siret N° 392 004 404 00019 - APE N° 741 A  
Brevets d'invention - Marques de Fabrique - Dessins et Modèles  
Procès en contrefaçon - Recherches d'antériorités - Consultations

**3, AVENUE BUGEAUD, 75116 PARIS - ☎ 01 45 53 05 50**

**Téléfax : 01 45 53 80 21 / 01 47 55 12 96 - E-mail : info@armengaud.fr**

**CERTIFICATE OF TRANSLATION**

**I, Chantal PEAUCELLE, European Patent Attorney, 3 Avenue  
Bugeaud, 75116 PARIS France,**

**Hereby state,**

**That, I am well acquainted with the French and English  
languages.**

**That the attached English translation is a true and correct  
translation of the text as approved for grant in connection with said  
FR patent 99 11133 to the best of my knowledge and belief.**

  
**Chantal PEAUCELLE**

**Paris, July 4, 2007**

Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA

5       The invention relates to means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA.

10       The T lymphocyte carries a receptor specific to the antigen against which it is directed, called TCR. This TCR is composed of several chains, the  $\alpha$  and  $\beta$  chains of which are involved in the specific recognition of a particular antigenic peptide presented in an HLA molecule. This recognition is shown by the ability of the  $\alpha/\beta$  TCR of the T lymphocyte to  
15       bind with a certain affinity to HLA-peptide complexes present on the surface of the target cell. Reciprocally, soluble HLA-peptide complexes are capable of binding to the TCR present on the surface of T lymphocytes specific to the HLA-peptide complex in question.

20

      At the present time, the system studied most at the molecular level is recognition by CD8+ T lymphocytes of antigenic peptides present in class I major histocompatibility complex (MHC) molecules, and in particular in the HLA-A0201  
25       allele.

      In this system, it has been established that the affinity of the TCR for the HLA-peptide complex is very low compared to the affinity of an antibody for its antigen. For this reason,  
30       detection of TCR-carrier lymphocytes which are reactive towards a specific peptide in this HLA context with the aid of soluble HLA-A0201 molecules which are charged with peptides and marked is impossible. To overcome this low affinity,

Altman et al (1) prepared a multivalent reagent composed of HLA-A0201-peptide complexes where the heavy chain of the HLA is biotinylated, which allows combination as a tetramer with streptavidine. This HLA-peptide tetramer has an increased avidity for the appropriate TCR-carrier T lymphocytes and can therefore be used to visualize reactive populations by immunofluorescence.

However, the TCR is not the only molecule of the T lymphocyte which can interact with the HLA-peptide complex. In fact, during physiological recognition the binding of the TCR to the MHC-peptide complex is intensified by binding of the co-receptor CD8 to a constant portion of class I MHC molecules. The participation of CD8 in the interaction varies from one lymphocyte clone to the other and in some cases can lead to a very significant increase in the capacity for binding to a given HLA-peptide complex. This ability of CD8 to bind to class I HLA consequently leads to a background noise of binding of class I HLA tetramers on the CD8+ T lymphocytes which carry TCR which are non-specific to the HLA-peptide complex. This background noise increases with the concentration of tetramer used and can lead to falsely positive immunofluorescence results. To attempt to reduce this non-specific marking, the majority of teams carry out their marking with class I HLA tetramers in the presence of anti-CD8 antibodies. However, only some anti-CD8 antibodies are effective and the optimum concentration ratios between the antibody and the tetramer must be readjusted for each test. As a result of these disadvantages, detection of specific sub-populations with a low representation within a non-specific population (for example of the order of 0.1 to 1%) becomes difficult.

Another potential application of HLA tetramers has moreover been proposed. This comprises isolation by screening (in flow cytometry or by immunomagnetic screening) of lymphocyte populations which are reactive towards a given HLA-peptide complex for the purpose of *in vitro* expansion and then therapeutic use within passive anti-viral or anti-tumoral immunization protocols. However, the background noise of binding of the tetramer due to the participation of CD8 may constitute a serious obstacle in this application, since it leads to isolation of an often significant fraction of T lymphocytes which are not reactive with respect to the selecting HLA-peptide complex.

Salter et al (2) have shown that binding of a membrane HLA expressed by cells transfected with a CD8 $\alpha$  co-receptor was modified when the HLA carried a mutation in the  $\alpha 3$  domain.

Study of such mutations by the inventors has led them to verify that soluble mutated tetramers effectively bind less CD8, regardless of whether  $\alpha\alpha$  or  $\alpha\beta$ , combined or not combined with a TCR on the surface of the T lymphocyte, which manifests itself in a reduction in the background noise.

It is therefore to be expected that the loss in affinity resulting from the mutation leads to a loss in the specific signal which is total or restricted to certain CD8-dependent T lymphocyte clones. In this respect, the article by Salter et al shows that certain CD8-dependent alloreactive clones lose their cytotoxicity with respect to cells carrying mutated HLA-A2, whereas others are less affected.

It would thus be possible that the mutated tetramers detect only a fraction of reactive cells (the less CD8-

dependent) within a polyclonal population.

5 The numerous comparative markings of polyclonal populations with mutated and native tetramers carried out by the inventors by double-marking with an anti-CD8 antibody demonstrate that, on the contrary, the mutated tetramer unexpectedly recognizes the same percentage of specific cells as the native tetramer.

10 Furthermore, comparison of the marking with the mutated tetramer on a highly CD8-dependent clone and a clone of low CD8 dependency shows a comparable effectiveness of the binding of the tetramer with respect to the intensity of the expression of the TCR.

15 It thus seems that the mutation very significantly reduces binding of the tetramer to CD8 alone, but affects its binding to the TCR-CD8 complex much less.

20 The invention therefore lies in the utilization of the properties demonstrated in mutated or, more generally, modified HLA multimers and provides such multimers and their complexes with antigenic peptides, as new products.

25 It also provides the use of these molecules for the detection and/or isolation of peptide-specific CD8+ T lymphocyte populations.

30 It additionally provides a method for detection and/or isolation of such populations with the aid of such molecules which are charged with peptide, in particular for applications in diagnostics and therapeutics.

The multimers according to the invention are built up from recombinant protein analogues of class I MHC and are characterized in that the proteins comprise at least one modification in the zone of interaction of a heavy chain of the class I MHC with the CD8 co-receptor of T lymphocytes, leading to a reduction, or even suppression of the affinity of the interaction between the heavy chain and the CD8.

The modification of the zone of interaction more specifically relates to the  $\alpha 3$  domain of the heavy chain.

More particularly, it is a mutation in the  $\alpha 3$  domain of at least one amino acid with respect to the corresponding domain of a native heavy chain which is capable of binding to the said CD8 co-receptor.

There may be mentioned by way of example the mutation of an alanine residue into a valine residue in position 245 of the  $\alpha 3$  domain of the HLA-A2 molecule.

The modification may also consist of a chemical modification of at least one amino acid and/or a deletion of at least one amino acid, this or these types of modification being in addition to one or more mutations, where appropriate.

The invention also provides, as new products, complexes built up from the multimers defined above and antigenic peptides.

In these complexes the multimers are present in particular in the form of tetramers.

According to the invention, these complexes are used for the detection and/or isolation of CD8+ T lymphocyte

populations which recognize the antigenic peptide of the complexes in a specific manner.

The use of the complexes defined above enables the  
5 background noise of non-specific binding to be reduced very significantly without modifying the specific marking and, in addition, removes the need for conjoint use of an anti-CD8 antibody during immunofluorescence analyses.

10 In a preferred use, the said complexes are used in a cell screening process, such as immunomagnetic screening.

An immunomagnetic screening technique for isolating specific T lymphocytes in mice is described by Luxembourg et  
15 al. (5).

This technique is based on the use of a system of beads  
coated with MHC-peptide complexes (produced in a Drosophilus system; charged with peptides and chemically biotinylated).

20 The invention also provides a method for detection and/or isolation of peptide-specific CD8+ T lymphocyte populations from a polyclonal population. The detection method is characterized in that it comprises:

- 25 - bringing the polyclonal population into contact with multimers complexed with antigenic peptides as defined above under conditions which allow interaction between the modified class I MHC complexes/peptides and T lymphocyte receptors which have an affinity for the said complexes,
- 30 - visualization of lymphocyte populations which are bound to the said complexes.

The visualization is carried out, for example, by

fluorescence using multimers comprising fluorescent compounds.

The method for isolation of peptide-specific lymphocyte populations from polyclonal populations also falls within the context of the invention and can be used, where appropriate, after the above detection stage.

This method utilizes the immunomagnetic screening technique and is characterized in that it comprises:

- 10       - bringing the polyclonal population into contact with magnetic beads on which are bound peptide/class I MHC analogue complexes as defined above under conditions which allow interaction between the said complexes and T lymphocyte receptors which have an affinity for these complexes,
- 15       - recovery of the bound populations, the screening operation being repeated, if desired, and/or followed, where appropriate, by a stage
- of in vitro amplification of the selected populations.

20       The increase in the differential between the background noise and specific marking with the modified multimers as defined above allows better discrimination of specific lymphocyte populations within a polyclonal population, and therefore makes immunomagnetic screening with these multimers  
25       very effective.

The MHC molecules comprise, for example, an enzymatic biotinylation moiety on the heavy chain. The beads on which the complexes are bound are coupled to streptavidine.

30

The polyclonal populations originate from samples taken from patients, such as synovial fluids or mononucleated cells of peripheral blood.



The amplification stage of selected populations is advantageously carried out by polyclonal stimulation under conditions which do not affect the representativeness of the amplified populations. PHA, IL2 or irradiated PBL, for example, are used.

The invention also provides T lymphocyte populations which have been selected and, where appropriate, amplified, characterized in that they are made up exclusively of T lymphocytes which are reactive towards the peptide of a given complex.

Such peptide-specific populations are of great interest in therapeutics, and more specifically for applications which rely on their re-administration in accordance with adoptive immunotherapy.

The invention thus provides pharmaceutical compositions, characterized in that they are developed from a peptide-specific T lymphocyte population as defined above in combination with a pharmaceutical vehicle.

Such compositions can advantageously be administered by injection.

It is thus possible to restore an antiviral or antitumoral immunity after injection of T lymphocytes which recognize, respectively, a defined class I MHC/viral or tumoral peptide complex, or to correct an immunity disequilibrium (for example the case of autoimmunity) by the administration of T cells directed against a given antigen and having activatory or inhibitory properties on the immune

response.

Other characteristics and advantages of the invention are given in the examples which follow, which are given purely by way of illustration and in which reference is made to figures 1 to 7, which show, respectively

- figures 1 and 2 show the fluorescence intensity (averages) as a function of the concentrations of native tetramers (1A, 2A) and of corresponding mutated tetramers (1B, 2B) with tetramers charged with peptide originating from BMLF1 (fig. 1) or pp65 (fig. 2),

- figure 3 shows the average fluorescence intensities as a function of the concentrations of native and mutated tetramers with specific clones,

- figure 4A shows the percentage of lysis, with or without anti-CD8 antibodies, of 2 specific clones of a B HLA-A0201 line charged with a BMLF1 peptide, and figures 4A and 4B show the results of the marking of these clones,

- figure 5 shows the results of single (with phycoerythrin, PE) and double (PE and marked anti-CD8 antibodies) marking of native and mutated tetramers with the lymphocytes of 2 patients and

- figures 6 and 7 show the results of immunomagnetic screening carried out with native tetramers and mutated tetramers.

Example 1 : Preparation of an HLA-A0201 tetramer mutated in the zone of interaction with the CD8 co-receptor.

A bacterial expression plasmid containing the cDNA which codes for the heavy chain of HLA-A0201, lengthened by a sequence which codes for an enzymatic biotinylation motive was used (construction according to Altman et al (1)). The

zone which codes for the  $\alpha 3$  domain had been amplified with the specific primers SEQ ID no. 1

5' CCTTCCAGAAGTGGGTGGCTGTGGTGGTGCC 3'

5 and SEQ ID no. 2

5' GGCACCACCACAGCCACCCACTTCTGGAAGG 3'

A mutation of a base to transform the alanine codon into a valine codon was introduced into the amplification fragments using the Stratagene QuickChange Site-directed Mutagenesis R kit.

The mutated fragment was reintroduced into the expression plasmid and the presence of the mutation was checked by sequencing.

The mutated HLA-A0201 heavy chain had been produced in the bacterial inclusion body and the HLA monomer charged with peptide, and then the corresponding mutated tetramer, could be obtained in accordance with a renaturation protocol previously described by Garboczi et al (3).

Example 2 : Comparative study of the effectiveness and specificity of immunofluorescent marking between a native HLA-A0201 tetramer and the mutated HLA-A0201 tetramer charged with different peptides.

1) Marking of lymphocyte clones

Native HLA-A0201 tetramers and corresponding mutated tetramers were charged either with a peptide originating from the protein BMLF1 of the EBV virus or with a peptide originating from the protein pp65 of CMV.

The native tetramers are obtained in accordance with the technique of example 1, but without the mutation.

Specific and non-specific clones were marked and used at  
5 increasing concentrations.

Figure 1 gives the average fluorescence intensity (AFI) obtained with the native HLA-A2/BMLF1 tetramers (figure 1A) and with the corresponding mutated tetramers (figure 1B).

10

It is found that the native HLA-A2/BM tetramer shows a background noise of binding on some non-specific clones which increases with the dose of tetramer used.

15

This background noise does not seem associated exclusively with the HLA restriction of the clone in question, but also depends on the peptide charged, since two HLA-A0201-restricted anti-IE1 clones give a high background noise, whereas the similarly HLA-A0201-restricted anti-melan-A clone  
20 gives a moderated background noise.

20

With the mutated tetramer, the averages of the fluorescence (AFI) obtained on the specific clones (BM/A2) are lower than those obtained with the native tetramer, but the  
25 background noise on the non-specific clones is virtually zero, regardless of the concentration of tetramer used.

25

It can be seen that this difference in background noise between the native tetramer and the mutated tetramer is not  
30 peculiar to the A2/BM tetramer, since it is also observed with the HLA-A2/pp65 tetramer (see figure 2).

30

In this figure 2, the average fluorescence is indicated

on a log scale in order to visualize the low background noise of marking obtained with the mutated tetramer. It is found that the differential between the specific marking and the non-specific marking is of the order of  $2 \log (10^2)$  with the mutated A2/pp65 tetramer, whereas it is only 1 log with the native tetramer. The two notable exceptions are the two anti-EBV CD4 clones, for which the background noise is very low with the native tetramer. This observation supports the hypothesis according to which the background noise of marking obtained with the native tetramer is due to a certain percentage of non-specific binding of the tetramer to CD8.

Figure 3 shows the marking differences obtained with the mutated and native tetramers charged with pp65 on specific clones. The difference between the saturation curves obtained with the mutated tetramer and the native tetramer show that there is a greater number of binding sites for the native tetramer than for the mutated tetramer on these clones: it is therefore highly probable that in the case of the native tetramer some valencies interact with the CD8 alone, especially since this molecule is expressed at a greatly higher density than that of TCR on the surface of the T lymphocyte.

Other experiments have been carried out to test whether the specific marking with the mutated tetramer was affected significantly by the degree of CD8-dependence of specific clones. In fact, it is well-known that among the T CD8+ clones, some clones have a high need of CD8 to intensify the specific interaction between their TCR and the HLA-peptide complex, while other clones dispense with it.

The degree of CD8 dependency was estimated by the

cytotoxicity test of Couedel et al (4) with or without anti-CD8 antibodies and is regarded as inversely proportional to the affinity of the TCR for the HLA-peptide complex.

5        Figure 4A shows a test of cytotoxicity against an HLA-A0201 line charged with BMLF1 peptide (10  $\mu$ M) with two specific clones. The clone A2.10 is highly CD8-dependent since its cytotoxicity is annulled by the anti-CD8 antibody, whereas the A4.5 clone has a relatively low CD8 dependency.

10        Marking with the mutated tetramer and marking with an anti-CD3 antibody was carried out to estimate the number of TCR expressed on the surface. The results are given in figures 4B (CD3 marking) and 4C (marking with the mutated  
15        BMFL1/A2 tetramer).

It is found that the ratio of tetramer marking/CD3 marking is very comparable for the two clones, which indicates that marking with the mutated tetramer is affected little by  
20        the degree of CD8 dependency (and thus, by inference, by the TCR affinity).

The reduction in the affinity for CD8 induced by the mutation of the HLA molecule thus does not significantly  
25        affect the specific marking of the tetramer.

b) Detection of specific cells within a polyclonal population

30        To compare the ability of the native and mutated tetramer to detect a small percentage of specific cells within a polyclonal population, peripheral lymphocytes from two HLA-A0201 patients (designated A and B below) were marked. These

are patients in whom an anti-CMV pp65 peptide response was demonstrated beforehand. These lymphocytes were amplified by polyclonal methods *in vitro* beforehand and frozen.

5       The results obtained for patients A and B are shown in figure 5, figure 5A corresponding to patient A and figure 5B to patient B. They are the results of single marking of HLA-A0201/pp65 tetramers with phycoerythrin in an amount of 20 µg/ml and corresponding double marking (tetramers marked with  
10 PE and anti-CD8 antibodies marked with FITC). This figure also gives the average fluorescence intensity (log).

Firstly, it is found that the discrimination ability of the native tetramer with single marking varies according to  
15 the percentage of specific cells in the starting population. In fact, for patient A, the peak of positive cells, which represents 5.60%, is easily identifiable, whereas for patient B this peak is contaminated by non-specific marking, which renders it difficult to determine the percentage of positive  
20 cells. In agreement with the literature, double marking of native tetramer and anti-CD8 reduces the background noise and therefore allows clear identification of the positive sub-population and precise estimation of its percentage (0.84% in this case). This thus shows that precise estimation of the  
25 percentage of positive cells with the native tetramer involves the use of double marking with anti-CD8.

On the other hand, single marking with the mutated tetramer allows identification without ambiguity of a peak of  
30 positive cells in the two patients. The percentages of positive cells obtained are virtually identical to those obtained with double marking with the native tetramer. This demonstrates that all the specific cells which can be detected

by the native tetramer are also detectable with the mutated tetramer, and thus corroborates the results obtained with the clones of high CD8 and low CD8 dependency, that is to say the mutation does not significantly affect the specific  
5 recognition.

Furthermore, these results show that the double marking with the mutated tetramer does not provide new elements with respect to single marking. Finally, it can be seen that the  
10 averages of the fluorescence obtained with the anti-CD8 antibodies with double marking with the native tetramer (216 and 193 for patients A and B) are significantly lower than those obtained with double marking with the mutated tetramer (366 and 370 for patients A and B). The averages of the  
15 fluorescence obtained after single marking of the total population with anti-CD8 were, respectively, 340 and 355 for patients A and B. This demonstrates the binding competition between the anti-CD8 antibody and the native tetramer, competition which does not result with the mutated tetramer.

20

The use of the mutated tetramer thus allows double marking with anti-CD8 to estimate the percentage of specific cells within a polyclonal population to be dispensed with.

25

Example 3: Comparative study of the effectiveness and specificity of immunomagnetic screening carried out with the native HLA-A0201 tetramer and the mutated HLA-A0201 tetramer charged with the peptide p65.

30

Biotinylated HLA-A0201 monomers charged with peptide pp65 were bound to magnetic beads coupled to streptavidine (Dynabeads M-280 Streptavidine, DYNAL). The lymphocyte populations used in the study originated from the synovial



fluids or PBL of patients suffering from rheumatoid polyarthrititis or PBL originating from healthy donors seropositive in respect of CMV.

5       The results of single marking with the native tetramer and the mutated tetramer on these polyclonal populations are shown in figure 6. With the mutated tetramer it is possible to demonstrate a low percentage of positive cells in the two samples (0.22% and 0.14%), positive cells which are virtually  
10       unidentifiable with the native tetramer.

      These populations were subjected to screening with beads charged either with the native tetramer or with the mutated tetramer, and the populations selected were then amplified in  
15       vitro by polyclonal stimulation (PHA, IL2, irradiated PBL), a stimulation which does not affect the representativeness of the amplified populations.

      Marking was then carried out on these populations which had  
20       been screened and amplified with the two tetramers.

      As shown in figure 6, the cells originating from screening with the native tetramer are marked positively with this same tetramer, but on the other hand a very low  
25       percentage of these cells are positive with the mutated tetramer (0.7% and 2.88%).

      The results are remarkably different after screening with the mutated tetramer, since the populations which have been  
30       screened are highly positive with the two tetramers.

      The concentration factor of positive cells obtained with the mutated tetramer is 421 for sample 1 (92.64% v. 0.22%) and

693 for sample 2 (97.01% v. 0.14%).

These results show that by screening with the mutated tetramer, it is possible to obtain a pure positive population  
5 of more than 90% from a sample in which this population represents 0.1 to 0.2%.

The general nature of this observation is illustrated by the table below, which describes the results of the screening  
10 carried out with the native tetramer and the mutated tetramer starting from PBL and synovial lymphocytes of patients and healthy donors.

% of positive cells of tetramers (concentration factor)

Samples	Not screened	First screening with		Second screening with	
		A2/pp65 native	A2/pp65 mutated	A2/pp65 native	A2/pp65 mutated
SFL 1	14.0	95.0 (6.8)			
PBL 1	5.6	89.5 (16.0)	97.9 (17.5)		
SFL 2	1.4	25.3 (18.1)		75.9 (3.0)	
PBL 2	0.8	51.1 (63.9)	97.5 (121.9)		
SFL 3	0.6	13.7 (22.8)			
PBL 3	nd	8.5 (nd)		12.0 (1.4)	
SFL 4	0.3	4.1 (13.6)		8.6 (2.1)	
SFL 5	0.2	0.7 (3.5)	92.5 (462.5)		
SFL 6	0.14	2.9 (20.6)	97.1 (693.6)		
PBL 4	0.00		82.9 (921.1)		
PBL 5	0.02	0.04 (2.0)	2.2 (110.0)	98.7 (44.90)	

By carrying out repeated screening with the mutated tetramer, it is possible to obtain pure specific populations from sub-populations which are even less frequent (cf. PBL5 in the table). On the other hand, this result is much more difficult to obtain with the native tetramer; it seems in fact that the non-specific cells isolated by a first screening with the native tetramer had an affinity sufficient to be selected again during the subsequent screening. Very mediocre concentration factors are thus arrived at by carrying out a second screening (cf. PBL3 and SFL4).

Another study related to the reactivity of populations which had been subjected to screening to verify that the cells selected for their ability to bind the mutated A2/pp65 tetramer were certainly reactive with respect to this HLA-peptide complex in a physiological context.

To this effect, the activation of screened lymphocyte populations, objectified by induction on the surface of the  $\alpha$  chain of the receptor for IL2 (CD25), after placing in the presence of T2 cells (A0201+) charged with peptide pp65, was studied.

As shown in figure 7, the populations which had been screened using the native tetramer do not express CD25 after contact with T2 cells charged with peptides.

On the other hand, the majority of these cells which have been screened with the mutated tetramer become activated in the presence of T2 charged with the peptide pp65 and the percentage of CD25-positive cells corresponds well with the percentage of cells which were marked by the mutated tetramer (90.63% of activated cells v. 92.64% of marked cells and

97.20% v. 97.01% for patients 1 and 2 respectively).

These results demonstrate that the cells marked and screened with the mutated tetramer are exclusively reactive cells, whereas the cells screened with the native tetramer are non-reactive.

The fact that no reactive cell is found after screening with the native tetramer whereas a distinction between some positive cells in this population was achieved is probably due to too low a percentage of these cells for them to be detectable in a functional test.

All of these results demonstrate the manifest superiority of the mutated tetramer with respect to the native tetramer for selection by immunomagnetic screening of populations with a low representation in the starting population.

If the specific populations are more numerous in the starting sample, it thus becomes possible to isolate reactive cells with the native tetramer, but the degrees of purity of the populations obtained are much lower than those obtained in parallel with the mutated tetramer (table).

## BIBLIOGRAPHY REFERENCES

- 1) Altman J.D. et al, 1996, Science 274:94-6 and US Patent 5 635 363
- 2) Salter, R.D. et al, 1990, Nature 345:41-46
- 3) Garboczi D.N. et al, 1992, Proc Natl Acad Sci USA 89:3429-33
- 4) Couedel, C., M. et al, 1999, J. Immunol 162-6351-B.
- 5) Luxembourg A.T. et al, Nature Biotechnology, vol. 16, March 1998, 281-285

## CLAIMS

1/ Multimers built up from recombinant proteins analogues of class I MHC, characterized in that the proteins comprise at least one modification in the zone of interaction of a heavy chain with the CD8 co-receptor of T lymphocytes leading to a reduction, or even suppression of the affinity of the interaction between the heavy chain and CD8.

2/ Multimers according to claim 1, characterized in that the modification relates to the  $\alpha 3$  domain of the heavy chain.

3/ Multimers according to claim 1 or 2, characterized in that the modification corresponds to a mutation in the  $\alpha 3$  domain of at least one amino acid, with respect to the corresponding domain of a native heavy chain capable of binding to the said CD8 co-receptor.

4/ Multimers according to claim 1 or 2, characterized in that the modification corresponds to chemical modification of at least one amino acid of the  $\alpha 3$  domain of a heavy chain, with respect to the corresponding domain of a native heavy chain capable of binding to the said CD8 co-receptor.

5/ Multimers according to claim 1 or 2, characterized in that the modification corresponds to the deletion of at least one amino acid of the  $\alpha 3$  domain of a heavy chain, with respect to the corresponding domain of a native heavy chain capable of binding to the said CD8 co-receptor.

6/ Multimers according to any one of claims 1 to 5, characterized in that they are in the form of complexes with antigenic peptides.

7/ Multimers according to claim 6, characterized in that they are in the form of tetramers.

8/ Use of multimers according to claim 6 or 7 for the purpose of detection and/or isolation of peptide-specific CD8+ T lymphocyte populations.

9/ Use according to claim 8 in a process for cell screening, such as immunomagnetic screening.

10/ Method for the detection of peptide-specific CD8+ T lymphocyte populations from a polyclonal population, characterized in that it comprises:

- bringing the polyclonal population into contact with multimers complexed with antigenic peptides according to claim 6 or 7 under conditions which allow interaction between the modified class I MHC/peptide complexes and T lymphocyte receptors which have an affinity for the said complexes,
- visualization of the lymphocyte populations which are bound to the said complexes.

11/ Method for isolation of peptide-specific CD8+ T lymphocyte populations from a polyclonal population, characterized in that it comprises:

- bringing the polyclonal population into contact with magnetic beads on which are bound the peptide/class I CMH analogue complexes according to claim 6 or 7 under conditions which allow interaction between the said complexes and T lymphocyte receptors which have an affinity for the said complexes,
- recovery of the bound populations, the screening operation being repeated, if desired, and/or followed, where appropriate, by a stage



- of *in vitro* amplification of the populations selected.


12/ Lymphocyte populations which have been selected and, where appropriate, amplified, characterized in that they are made up exclusively of T lymphocytes which are reactive towards the peptide of a complex with multimers according to claim 6 or 7.

13/ Pharmaceutical compositions which can be used, in particular, in immunotherapy, characterized in that they are built up from a lymphocyte population according to claim 12 in combination with a pharmaceutically inert vehicle.

Figure 1A

## HLA-A2/BMLF1 tetramer

FIGURE 1



- A2.10 BM/A2
- A4.5 BM/A2
- LP16 IE1/A2
- ◇ LP23 IE1/A2
- ▽ Melan-A/A2
- ◆ BZ/B18
- \* BZ/B14
- ⊕ Tyrosinase/B35
- ⊞ 22.19 BZ/B40

Figure 1 B

## Mutated HLA-A2/BMLF1 tetramer




FIGURE 2




FIGURE 3




FIGURE 4

FIGURE 4A




FIGURE 4B



CD3  
marking


FIGURE 4C

mutated  
Bm1f1/A2  
tetramer  
marking

Ratio of mutated tetramer AFI/CD3 AFI

A2.10: 0,43

A4.5: 0,47



Marking before screening

6/7

FIGURE 6





Marking after screening with normal A2/pp65 tetramerMarking after screening with mutated A2/pp65 tetramer

FIGURE 7

Patient 1Patient 2